Purpose: The aim of this pilot study was to evaluate the potential neuroprotective effect of an
intravitreal injection of erythropoietin (EPO) on retinal ganglion cell (RGC) preservation in an …

purpose. Retinal ganglion cell (RGC) loss occurs in response to increased intraocular
pressure (IOP) and/or retinal ischemia in glaucoma and leads to impairment of vision. This …

Purpose: The present study aimed to assess functional and structural benefits of
erythropoietin (EPO) when administered subconjunctivally in the retina of glaucomatous rats …

Purpose: To determine the aqueous concentration of erythropoietin (EPO) in patients with
and without glaucoma. Methods: Prospective, comparative control study. Concentrations of …

Objective: The aim of this study was to clarify whether erythropoietin (EPO) with a retrobulbar
administration could protect retinal ganglion cells (RGCs) from acute elevated intraocular …

Purpose To evaluate the levels of erythropoietin (EPO) in the aqueous humor in eyes with
primary open-angle glaucoma (POAG) and without glaucoma. Methods Levels of EPO were …

Purpose To compare the aqueous concentration of erythropoietin (EPO) in eyes with primary
open-angle (POAG), pseudoexfoliative (PXFG), and neovascular (NVG) glaucoma with age …

Glaucoma is a progressive optic neuropathy that is the leading cause of irreversible
blindness in the world. Although methods to lower intraocular pressure are the mainstay of …

purpose. Recent studies have reported neuroprotective effects of erythropoietin (EPO) and
vascular endothelial growth factor (VEGF). The purpose of the present study was to clarify …

Aims Recent studies have showed that erythropoietin (EPO) is a neuroprotectant for central
nerve system neurons in addition to being a hematopoietic cytokine in response to hypoxia …